HK1257844A1 - 藥物化合物的嘌呤和氮雜嘌呤衍生物 - Google Patents

藥物化合物的嘌呤和氮雜嘌呤衍生物

Info

Publication number
HK1257844A1
HK1257844A1 HK19100201.4A HK19100201A HK1257844A1 HK 1257844 A1 HK1257844 A1 HK 1257844A1 HK 19100201 A HK19100201 A HK 19100201A HK 1257844 A1 HK1257844 A1 HK 1257844A1
Authority
HK
Hong Kong
Prior art keywords
purine
pharmaceutical compounds
deazapurine derivatives
deazapurine
derivatives
Prior art date
Application number
HK19100201.4A
Other languages
English (en)
Inventor
Thomas Glanmor Davies
Robert George Boyle
Ian Collins
Original Assignee
Astex Therapeutics Ltd
The Institute Of Cancer Res Royal Cancer Hospital
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608179A external-priority patent/GB0608179D0/en
Priority claimed from GB0608176A external-priority patent/GB0608176D0/en
Application filed by Astex Therapeutics Ltd, The Institute Of Cancer Res Royal Cancer Hospital, Cancer Research Tech Ltd filed Critical Astex Therapeutics Ltd
Publication of HK1257844A1 publication Critical patent/HK1257844A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK19100201.4A 2006-04-25 2009-08-20 藥物化合物的嘌呤和氮雜嘌呤衍生物 HK1257844A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0608179A GB0608179D0 (en) 2006-04-25 2006-04-25 Pharmaceutical compounds
GB0608176A GB0608176D0 (en) 2006-04-25 2006-04-25 Pharmaceutical Compounds

Publications (1)

Publication Number Publication Date
HK1257844A1 true HK1257844A1 (zh) 2019-11-01

Family

ID=38255445

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100201.4A HK1257844A1 (zh) 2006-04-25 2009-08-20 藥物化合物的嘌呤和氮雜嘌呤衍生物

Country Status (7)

Country Link
US (1) US8796293B2 (zh)
EP (3) EP3719018A1 (zh)
JP (1) JP5606734B2 (zh)
DK (1) DK3421471T3 (zh)
ES (1) ES2878130T3 (zh)
HK (1) HK1257844A1 (zh)
WO (1) WO2007125321A2 (zh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
ES2558517T3 (es) * 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
US7851484B2 (en) 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
SI2201012T1 (sl) 2007-10-11 2014-10-30 Astrazeneca Ab Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
AU2008331733A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1H- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase C-theta
CN101959887B (zh) 2008-01-08 2013-07-31 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
ES2392014T3 (es) 2008-01-09 2012-12-03 Array Biopharma, Inc. Pirazolopiridinas como inhibidores de la cinasa
AU2009239500B2 (en) 2008-04-21 2014-01-30 Lexicon Pharmaceuticals, Inc. LIMK2 inhibitors, compositions comprising them, and methods of their use
AU2013218743B2 (en) * 2008-05-13 2016-04-28 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
MX2012004780A (es) 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
RU2565034C2 (ru) * 2010-02-03 2015-10-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Идентификация мутации lkb1 в качестве прогностического биомаркера чувствительности к ингибиторам tor-киназы
WO2012080735A1 (en) 2010-12-16 2012-06-21 Convergence Pharmaceuticals Limited Ask1 inhibiting pyrrolopyrimidine derivatives
DK2694056T3 (da) 2011-04-01 2020-01-02 Astrazeneca Ab Terapeutisk behandling
EA028060B1 (ru) 2011-07-13 2017-10-31 Сайтокинетикс, Инк. Комбинированная терапия бокового амиотрофического склероза
ES2646759T3 (es) * 2011-09-12 2017-12-15 Merck Patent Gmbh Derivados de aminopirimidina para uso como moduladores de la actividad de la quinasa
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
MY175800A (en) 2011-11-30 2020-07-09 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
RU2619465C2 (ru) * 2012-10-26 2017-05-16 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
WO2014086453A1 (en) * 2012-12-07 2014-06-12 Merck Patent Gmbh Azaheterobicyclic compounds
TWI654979B (zh) 2013-04-17 2019-04-01 美商標誌製藥公司 使用tor激酶抑制劑組合療法以治療癌症之方法
TWI656875B (zh) 2013-04-17 2019-04-21 美商標誌製藥公司 藉二氫吡并吡治療癌症
KR102271344B1 (ko) 2013-04-17 2021-07-01 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
KR102221005B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
WO2014172423A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用tor激酶抑制劑組合療法以治療癌症之方法
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2018507236A (ja) * 2015-03-04 2018-03-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トリアゾロピリジン化合物及びその使用法
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2021143680A1 (zh) 2020-01-16 2021-07-22 浙江海正药业股份有限公司 杂芳基类衍生物及其制备方法和用途
WO2021194607A1 (en) * 2020-03-25 2021-09-30 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat frontotemporal dementia
WO2023183394A1 (en) * 2022-03-24 2023-09-28 Curasen Therapeutics, Inc. Alpha 1a-adrenergic receptor agonists and methods of use

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (zh) 1963-04-04 1900-01-01
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
IT1252567B (it) 1991-12-20 1995-06-19 Italfarmaco Spa Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
JP2001519766A (ja) 1996-04-03 2001-10-23 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼの阻害剤
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
TR200000333T2 (tr) 1997-08-05 2000-05-22 Pfizer Products Inc. Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler.
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
ID27600A (id) 1998-06-02 2001-04-12 Osi Pharm Inc KOMPOSISI PIROLO (2,3d) PIRIMIDIN DAN PENGGUNAANNYA
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
ID26698A (id) 1998-06-19 2001-02-01 Pfizer Prod Inc SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
EP1244672B1 (en) 1999-12-21 2005-07-20 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
CN1308324C (zh) 2000-08-31 2007-04-04 弗·哈夫曼-拉罗切有限公司 作为α-1肾上腺素能拮抗剂的喹唑啉衍生物
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
HUP0400692A3 (en) 2000-12-01 2007-09-28 Osi Pharmaceuticals Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CN100503608C (zh) 2002-01-07 2009-06-24 卫材R&D管理株式会社 脱氮嘌呤及其用途
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
TW200410688A (en) * 2002-06-26 2004-07-01 Ono Pharmaceutical Co Therapeutics for diseases from vasoconstriction or vasodilatation
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
EP1567495A4 (en) 2002-11-08 2007-10-31 Harvard College SMALL, WITH TECHNETIUM-99M AND RHENIUM-MARKED MEDIUM AND METHOD OF ILLUMINATING WOVEN FABRICS, ORGANS AND TUMORS
RU2328498C9 (ru) 2002-12-04 2008-12-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Соединения с конденсированным 1,3-дигидроимидазольным циклом
EP1444982A1 (de) * 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
SE0300457D0 (sv) 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
MXPA05009722A (es) 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
CN1720246A (zh) 2003-04-21 2006-01-11 捷克共和国乌斯塔夫化学与生物化学研究院 (嘌呤-6-基)氨基酸及其制备方法
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス, インコーポレイテッド c−Kit調節因子および使用方法
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
CN1882347A (zh) 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
US7511159B2 (en) * 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880540B1 (fr) * 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
WO2007125325A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
EP2013206A1 (en) 2006-04-25 2009-01-14 Astex Therapeutics Limited Pharmaceutical compounds
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
SI2201012T1 (sl) 2007-10-11 2014-10-30 Astrazeneca Ab Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B

Also Published As

Publication number Publication date
US20100022564A1 (en) 2010-01-28
EP3719018A1 (en) 2020-10-07
JP5606734B2 (ja) 2014-10-15
EP3421471A1 (en) 2019-01-02
DK3421471T3 (da) 2021-06-14
WO2007125321A3 (en) 2007-12-27
US8796293B2 (en) 2014-08-05
WO2007125321A2 (en) 2007-11-08
EP2043655A2 (en) 2009-04-08
ES2878130T3 (es) 2021-11-18
JP2009534455A (ja) 2009-09-24
EP3421471B1 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
HK1257844A1 (zh) 藥物化合物的嘌呤和氮雜嘌呤衍生物
IL202622A (en) Purin derivatives and pharmaceuticals containing them
IL194460A0 (en) Deazapurine derivatives and pharmaceutical compositions containing the same
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
IL193240A0 (en) Dihydrodiazepine derivatives and pharmaceutical compositions containing the same
GB2450753B (en) New Pharmaceutical formulation
IL191902A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL196601A0 (en) Pyrimidine derivatives and pharmaceutical compositions containing the same
ZA200808530B (en) Pharmaceutical composition for external use
ZA200809002B (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
IL196033A0 (en) Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
ZA200808531B (en) Pharmaceutical composition for external use
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
IL191531A0 (en) Orally absorbed pharmaceutical formulation
HK1125295A1 (zh) 基於微片的藥物製劑
AP2008004671A0 (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
GB0614586D0 (en) Pharmaceutical Formulation
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
ZA200702234B (en) Preparation of ester of purine derivatives
GB0719248D0 (en) Compounds and methods for pharmaceutical use
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
IL198160A0 (en) Pharmaceutical formulations
GB0608176D0 (en) Pharmaceutical Compounds

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: GARRETT, MICHELLE, DAWN

Effective date: 20211130